|
KMID : 0311120230640080489
|
|
Yonsei Medical Journal
2023 Volume.64 No. 8 p.489 ~ p.496
|
|
|
Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality
|
|
Kim Eui-Hyun
Kim Jun-Hyung
Ku Cheol-Ryong
Lee Eun-Jig
Kim Sun-Ho
|
|
|
Abstract
|
|
|
Purpose: Treatment with dopamine agonists (DAs) has been the first-line standard treatment for prolactinoma, and surgery has been reserved for drug intolerance and resistance for several decades. We evaluated whether surgery plays a primary role in pro lactinoma management.
Materials and Methods: We conducted a retrospective study of 210 prolactinoma patients who had received surgical treatment at our institution. We analyzed the treatment outcomes according to tumor extent, sex, and preoperative DA medication.
Results: Overall hormonal remission was achieved in 164 patients (78.1%), and complete removal was achieved in 194 patients (92.4%). When the tumors were completely removed, the remission rate increased to 84.5%. Anterior pituitary function was nor malized or improved in 94.6% of patients, whereas only 4.1% of patients showed worsening of hormone control. Hormonal remis sion was higher in patients who had not received DA preoperatively than in those who had received preoperative DA treatment. Smaller tumor size (<1 cm), no invasion into the cavernous sinus, and female sex were predictors of good surgical outcomes.
Conclusion: Although DAs remain the first-line standard treatment for prolactinomas, surgery can be an excellent option and should be considered as an alternative primary treatment modality when patients are predicted to achieve a good surgical outcome.
|
|
|
KEYWORD
|
|
|
Dopamine agonist, pituitary adenoma, prolactinoma, transsphenoidal surgery
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|